Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 9, Pages e002794
Publisher
BMJ
Online
2021-09-13
DOI
10.1136/jitc-2021-002794
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
- (2021) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).
- (2021) Mark Yarchoan et al. JOURNAL OF CLINICAL ONCOLOGY
- mRNA vaccine for cancer immunotherapy
- (2021) Lei Miao et al. Molecular Cancer
- PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
- (2021) David J. Pinato et al. BMC CANCER
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- (2021) Julie R Brahmer et al. Journal for ImmunoTherapy of Cancer
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2020) Peter R. Galle et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis
- (2020) Jiaxin Zhang et al. PLoS One
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
- (2020) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
- (2020) Sirish Dharmapuri et al. Cancer Medicine
- Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
- (2020) Won Jin Ho et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
- (2020) Patrick Boland et al. Journal for ImmunoTherapy of Cancer
- LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
- (2020) B. Sangro et al. ANNALS OF ONCOLOGY
- Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
- (2020) Arsen Osipov et al. CLINICAL CANCER RESEARCH
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- 997P PD-L1 protein expression as a predictor of response to immune checkpoint inhibitor (ICI) in hepatocellular carcinoma (HCC): A meta-analysis
- (2020) Z. Wang et al. ANNALS OF ONCOLOGY
- Hyperprogression in hepatocellular carcinoma: Illusion or reality?
- (2020) Stephen L. Chan JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
- (2020) Petros Fessas et al. Journal for ImmunoTherapy of Cancer
- Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240
- (2020) Baek‐Yeol Ryoo et al. CANCER
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- CT/MR LI-RADS 2018: clinical implications and management recommendations
- (2019) Amita Kamath et al. Abdominal Radiology
- Combined locoregional-immunotherapy for liver cancer
- (2019) Tim F. Greten et al. JOURNAL OF HEPATOLOGY
- Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
- (2019) Daniel Jiahao Wong et al. Immunotherapy
- Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib
- (2019) Young Mi Hong et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients with End-Stage Liver Disease
- (2019) Nneka N. Ufere et al. Clinical Gastroenterology and Hepatology
- Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- Hyperprogression under Immunotherapy
- (2019) Frelaut et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
- (2019) María González-Cao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
- (2019) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
- (2019) Annie Wong et al. ONCOLOGIST
- Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
- (2019) Noha Abdel-Wahab et al. Journal for ImmunoTherapy of Cancer
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
- (2019) Swetha Kambhampati et al. CANCER
- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC Guidelines) a 2019 update
- (2019) Norihiro Kokudo et al. HEPATOLOGY RESEARCH
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
- (2019) Thomas S. Uldrick et al. JAMA Oncology
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
- (2019) David J. Pinato et al. JAMA Oncology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Anti-drug Antibodies Against Immune Checkpoint Blockers: Impairment of drug efficacy or indication of immune activation?
- (2019) Diego Enrico et al. CLINICAL CANCER RESEARCH
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
- (2019) Jan Best et al. Clinical Gastroenterology and Hepatology
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
- (2019) Bridget P. Keenan et al. Journal for ImmunoTherapy of Cancer
- Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status
- (2019) Mohit Butaney et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
- (2019) Neil J. Shah et al. Journal for ImmunoTherapy of Cancer
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma
- (2018) Nicole E. Rich et al. Clinical Gastroenterology and Hepatology
- Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults
- (2018) Christopher D. Woodrell et al. CLINICAL THERAPEUTICS
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study
- (2018) T. Meyer et al. JOURNAL OF HEPATOLOGY
- Targets for immunotherapy of liver cancer
- (2018) Tim F. Greten et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- mRNA vaccines — a new era in vaccinology
- (2018) Norbert Pardi et al. NATURE REVIEWS DRUG DISCOVERY
- Use of checkpoint inhibitors in liver transplant recipients
- (2018) Stefan Munker et al. United European Gastroenterology Journal
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome
- (2018) Mohammed Alnaggar et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
- (2018) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
- (2018) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
- (2018) Luigi Buonaguro et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient performance status and cancer immunotherapy efficacy: a meta-analysis
- (2018) Melissa Bersanelli et al. MEDICAL ONCOLOGY
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients
- (2018) Victoria Chernyak et al. RADIOLOGY
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment
- (2018) S K Qin et al. ANNALS OF ONCOLOGY
- GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score
- (2018) Ju Dong Yang et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study
- (2018) David J. Pinato et al. JOURNAL OF CLINICAL ONCOLOGY
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
- (2017) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis
- (2017) Tomohiro F. Nishijima et al. ONCOLOGIST
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Hepatocellular carcinoma in patients with HIV
- (2017) Imane El Dika et al. Current Opinion in HIV and AIDS
- Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer
- (2017) Mao Lin et al. Oncotarget
- Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization
- (2017) Bin Gui et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
- (2016) A. Blythe Ryerson et al. CANCER
- The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma
- (2016) Katie E. Rollins et al. CLINICAL NUTRITION
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors
- (2016) K. Robin Yabroff et al. JOURNAL OF CLINICAL ONCOLOGY
- Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs
- (2016) Ashley E. Glode et al. PHARMACOTHERAPY
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
- (2016) Yu Sawada et al. OncoImmunology
- The Impact Of Hepatitis B Knowledge and Stigma on Screening in Canadian Chinese Persons
- (2016) Dorothy Li et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Building the Multidisciplinary Team for Management of Patients With Hepatocellular Carcinoma
- (2015) Willscott E. Naugler et al. Clinical Gastroenterology and Hepatology
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging and Multidetector-Row Computed Tomography for the Diagnosis of Hepatocellular Carcinoma
- (2015) Feng Ye et al. MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging—A Systematic Review and Meta-Analysis
- (2015) Yoon Jin Lee et al. RADIOLOGY
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
- (2015) A. R. Sanchez-Paulete et al. Cancer Discovery
- Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled
- (2015) Sam S. Oh et al. PLOS MEDICINE
- Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma
- (2015) Robert F. Hanna et al. Abdominal Radiology
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
- (2015) Bruno Vincenzi et al. PLoS One
- ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
- (2014) Jorge A Marrero et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib
- (2014) You-Bing Zheng et al. Asian Pacific Journal of Cancer Prevention
- The Therapeutic Use of Analgesics in Patients with Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations
- (2014) Farnad Imani et al. Hepatitis Monthly
- Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells
- (2014) Angela D. Pardee et al. JOURNAL OF IMMUNOLOGY
- Access to Chemotherapy Services by Availability of Local and Visiting Oncologists
- (2014) Marcia M. Ward et al. Journal of Oncology Practice
- Impact of Financial Burden of Cancer on Survivors' Quality of Life
- (2014) Kathleen M. Fenn et al. Journal of Oncology Practice
- Screening for Liver Cancer: The Rush to Judgment
- (2013) Frank A. Lederle ANNALS OF INTERNAL MEDICINE
- Rural Residence and Cancer Outcomes in the United States: Issues and Challenges
- (2013) A. Meilleur et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Palliative Care and End-Stage Liver Disease
- (2013) Anne M. Walling et al. Clinical Gastroenterology and Hepatology
- Patients With Cirrhosis and Denied Liver Transplants Rarely Receive Adequate Palliative Care or Appropriate Management
- (2013) Zafrina Poonja et al. Clinical Gastroenterology and Hepatology
- Consequences of Perceived Stigma Among Patients with Cirrhosis
- (2013) Valerie Vaughn-Sandler et al. DIGESTIVE DISEASES AND SCIENCES
- Health care costs associated with hepatocellular carcinoma: A population-based study
- (2013) Hla-Hla Thein et al. HEPATOLOGY
- Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer
- (2013) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
- (2013) Shin Yoshimoto et al. NATURE
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
- (2013) S. Y. Zafar et al. ONCOLOGIST
- Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging
- (2013) Fernanda D. Gonzalez-Guindalini et al. RADIOGRAPHICS
- mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
- (2012) H. J. Prajapati et al. ANNALS OF ONCOLOGY
- A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
- (2012) Tim F Greten et al. BMC CANCER
- Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
- (2012) Dianne H. Dapito et al. CANCER CELL
- Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
- (2012) Y. Sawada et al. CLINICAL CANCER RESEARCH
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma
- (2012) Momar Diouf et al. JOURNAL OF HEPATOLOGY
- Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
- (2012) Beom Kyung Kim et al. LIVER INTERNATIONAL
- Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping
- (2012) Sheng-Yu Fan et al. PSYCHO-ONCOLOGY
- Systemic Therapy in Hepatocellular Carcinoma
- (2011) Stephen H. Wrzesinski et al. Clinics in Liver Disease
- Illness experience in patients with hepatocellular carcinoma
- (2011) Sheng-Yu Fan et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Selecting an optimal staging system for hepatocellular carcinoma
- (2010) Chia-Yang Hsu et al. CANCER
- Health-Related Quality of Life in Patients With Hepatocellular Carcinoma: A Systematic Review
- (2010) Sheng–Yu Fan et al. Clinical Gastroenterology and Hepatology
- Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?
- (2010) Fidel-David Huitzil-Melendez et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- (2010) Jennifer S. Temel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal
- (2009) Franco Trevisani et al. DIGESTIVE AND LIVER DISEASE
- Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients
- (2009) A. Vitale et al. TRANSPLANTATION PROCEEDINGS
- Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis
- (2008) M A Silva et al. GUT
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
- (2008) Daniel H. Palmer et al. HEPATOLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
- (2008) Vincenzo Mazzaferro et al. LANCET ONCOLOGY
- Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
- (2008) Franck Bonnetain et al. QUALITY OF LIFE RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now